| Primary |
| Drug Use For Unknown Indication |
26.0% |
| Cerebral Toxoplasmosis |
12.0% |
| Congenital Toxoplasmosis |
12.0% |
| Infection Protozoal |
12.0% |
| Agitation |
8.0% |
| Hiv Infection |
8.0% |
| Antiretroviral Therapy |
4.0% |
| Opportunistic Infection Prophylaxis |
4.0% |
| Toxoplasmosis |
4.0% |
| Antiviral Prophylaxis |
2.0% |
| Brain Oedema |
2.0% |
| Infection Prophylaxis |
2.0% |
| Malaria Prophylaxis |
2.0% |
| Tay-sachs Disease |
2.0% |
|
| Maternal Drugs Affecting Foetus |
12.5% |
| Convulsion |
6.3% |
| Hyperthermia |
6.3% |
| Infection Reactivation |
6.3% |
| Leukopenia |
6.3% |
| Microangiopathy |
6.3% |
| Neutropenia |
6.3% |
| Ophthalmoplegia |
6.3% |
| Oxygen Saturation Decreased |
6.3% |
| Renal Failure Acute |
6.3% |
| Respiratory Failure |
6.3% |
| Status Epilepticus |
6.3% |
| Stillbirth |
6.3% |
| Ventricular Extrasystoles |
6.3% |
| Vomiting |
6.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
28.1% |
| Hiv Infection |
12.9% |
| Toxoplasmosis |
11.1% |
| Cerebral Toxoplasmosis |
8.8% |
| Acquired Immunodeficiency Syndrome |
6.0% |
| Product Used For Unknown Indication |
5.4% |
| Agitation |
3.9% |
| Antifungal Prophylaxis |
3.8% |
| Opportunistic Infection Prophylaxis |
3.8% |
| Eye Infection Toxoplasmal |
2.1% |
| Antiretroviral Therapy |
1.9% |
| Brain Oedema |
1.9% |
| Toxoplasmosis Prophylaxis |
1.9% |
| Prophylaxis |
1.7% |
| Antiviral Prophylaxis |
1.3% |
| Ill-defined Disorder |
1.3% |
| Antiviral Treatment |
1.1% |
| Epilepsy |
1.1% |
| Adverse Drug Reaction |
0.9% |
| Aspergillosis |
0.9% |
|
| Neutropenia |
14.1% |
| Pancytopenia |
9.9% |
| Treatment Noncompliance |
9.9% |
| Ventricular Extrasystoles |
9.9% |
| Thrombocytopenia |
7.0% |
| Aspartate Aminotransferase Increased |
5.6% |
| Rash |
5.6% |
| Toxic Epidermal Necrolysis |
5.6% |
| Acute Graft Versus Host Disease In Skin |
2.8% |
| Blindness Unilateral |
2.8% |
| Cytolytic Hepatitis |
2.8% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.8% |
| Jaundice |
2.8% |
| Renal Failure Acute |
2.8% |
| Respiratory Distress |
2.8% |
| Respiratory Failure |
2.8% |
| Serum Ferritin Increased |
2.8% |
| Staphylococcal Sepsis |
2.8% |
| Zygomycosis |
2.8% |
| Aspergillosis |
1.4% |
|
| Concomitant |
| Hiv Infection |
34.9% |
| Drug Use For Unknown Indication |
27.2% |
| Toxoplasmosis |
8.3% |
| Cerebral Toxoplasmosis |
6.4% |
| Antibiotic Prophylaxis |
3.3% |
| Hodgkin's Disease |
2.6% |
| Product Used For Unknown Indication |
2.6% |
| Prophylaxis |
1.9% |
| Hiv Test Positive |
1.4% |
| Bacterial Infection |
1.3% |
| Antiviral Prophylaxis |
1.2% |
| Nausea |
1.2% |
| Opportunistic Infection Prophylaxis |
1.2% |
| Acquired Immunodeficiency Syndrome |
1.0% |
| Antifungal Prophylaxis |
1.0% |
| Cardiomyopathy |
1.0% |
| Convulsion |
1.0% |
| Pneumocystis Jiroveci Pneumonia |
0.9% |
| Vomiting |
0.9% |
| Cytomegalovirus Enterocolitis |
0.8% |
|
| Vomiting |
18.1% |
| Weight Increased |
9.6% |
| Femoral Neck Fracture |
7.2% |
| Rash Maculo-papular |
7.2% |
| Rash |
6.0% |
| Mental Status Changes |
4.8% |
| Toxoplasmosis |
4.8% |
| Epilepsy |
3.6% |
| Insomnia |
3.6% |
| Liver Function Test Abnormal |
3.6% |
| Nystagmus |
3.6% |
| Respiratory Distress |
3.6% |
| Sepsis |
3.6% |
| Stevens-johnson Syndrome |
3.6% |
| Streptococcal Infection |
3.6% |
| Tachypnoea |
3.6% |
| Acute Febrile Neutrophilic Dermatosis |
2.4% |
| Cerebral Toxoplasmosis |
2.4% |
| Drug Interaction |
2.4% |
| Drug Level Decreased |
2.4% |
|
